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Tissue engineering and ENT surgery
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Abstract
Tissue engineering is the development of biological substitutes for the repair and regeneration of
damaged tissues. We explain the principles of this emerging eld of biotechology. The present and
potential applications of tissue engineering technologies in ENT surgery are then reviewed.
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Introduction
A large part of modern medical practice is aimed at
the restoration of function by replacement or repair
of damaged tissues or organs. This is achieved either
by using articial implants or by transplantation of
tissues. Factors such as immune rejection, limited
supply, donor site morbidity and infection risk, are a
constant risk. Specically in Otorhinolaryngology–
Head and Neck surgery, disease processes and
therapeutic interventions result in destruction or
malformation of tissues and organs such as the
trachea, pinna, nasal cartilages, ossicles and mand-
ible. Reconstruction of these and other head and
neck structures remain a great challenge. Tissue
engineering, which represents an alternative philo-
sophy, offers the scope to repair and replace
damaged tissue with specically constructed living
tissue.
Tissue engineering may be dened as a multi-
disciplinary approach combining principles of engi-
neering and life sciences for developing living
prefabricated replacement tissue and organs tailored
to the needs of the individual. Broader denitions
include regeneration and repair by cell transplanta-
tion, insertion of acellular bioactive scaffolds and
even in vitro induction of cellular regeneration.1,2
Tissue engineering approaches have been pursued
for decades,1,3–5 and by the 1990s tissue engineering
developed into a cross-speciality discipline in its own
right.5
With an estimated total market potential of tissue-
engineering products in the USA being $80 billion
per annum it is not surprising that the tissue
engineering industry is burgeoning.1,5,6 The number
of patent applications alone bear astonishing testa-
ment to the commercial interest in the discipline.7
However, there are some who would question the
ethics of granting patents for many of these
‘discoveries’.
Scientic interest in the eld is escalating, with
articles appearing in leading scientic and clinical
journals.1,8–10 The journal Science featured research
on embryonic stem cells (a core research area in
tissue engineering) as their ‘breakthrough of the year
1999’.11 The eld has also attracted media interest;
Time magazine in a series of articles on life in the
21st century predicted ‘tissue engineer’ as the
number one job of the future.12
The tissue engineering process
Tissues are composed of cells and extracellular
matrix. Most tissue engineering processes, therefore,
involve the replacement of cells afliated with a
matrix of scaffold to form a construct for implanta-
tion. However, some techniques are reliant solely on
cells, others solely on matrices.
The steps involved in the creation of living tissues
and organs for replacement illustrate the need for a
wide-ranging skill mix for successful tissue engineer-
ing. The primary step is cell harvest. A suitable
donor source for the cells is identied and a viable
sample of the appropriate cell type is separated from
the donor tissue. The cells usually require a scaffold
onto which they are seeded and may survive. Figure
1 shows cells attached to a scaffold. The sample cell
population must then be nurtured to proliferate to at
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least a viable cell number. Maintenance or develop-
ment of specialist characteristics ie. cellular
differentiation is the next essential step towards a
prefabricated replacement construct which is then
transplanted to the recipient patient. This process is
outlined in Figure 2.
During these processes there are three funda-
mental issues that need to be addressed before any
tissue-engineering therapy becomes a clinical reality.
These are the size, complexity and stability of tissue
constructs.
Animal cell culture and indeed human cell culture
techniques are readily available to grow two dimen-
sional colonies of cells in vitro up to sizes of a few
square millimetres. Indeed techniques have now
been developed to grow three dimensional colonies
in vitro and in vivo.13–15 To overcome the limitations
of diffusion for cellular nutrition and excretion to
allow cell survival to be maintained inside large
three-dimensional constructs there is extensive inter-
est in neovascularization11 and the development of
prevascularized engineered solid organs.16
Tissues and organs are composed of multiple types
of cells and cellular matrices. This complexity cannot
be overlooked, a tissue-engineered construct
requires a similar level of multi-cellular and three-
dimensional structure.
As with transplantation of allograft or xenograft
donor organs the long-term stability of a tissue-
engineered construct is of paramount importance.
Factors affecting the long-term stability of the cells,
the scaffold and the cell-scaffold unit are relevant.
Scaffold degeneration may be due to an immune
response, the scaffold’s inherent physicochemical
nature and due to the physicochemical stresses of the
newly implanted organ, for example the potential
mechanical forces acting upon an implanted articular
cartilage construct within a joint. Different methods
are being explored to avoid host rejection of the
cellular elements of the construct, these include the
use of cells that are modied to be immunotolerant,
or the use of pluripotent embryonic stem cells after
transfer of the genetic code of the patients’ own
nucleus.17
The cells of the tissue-engineered construct
The donor cells that are used may be adult or
embryonic. Adult cells may be committed or stem
cells. Embryonic cells are pluripotent stem cells.
Committed adult cell lines from a variety of tissues
have been cultured and investigated for their tissue-
engineering applications. In some tissues limitations
exist however, relating to aspects of cell harvest, the
ability of cells to proliferate and/or the maintenance
of cellular differentiation. Autologous cells are by
denition immunoprivileged, however, the ability to
utilize allogenic cell sources would expand the scope
of tissue engineering in part by the creation of
therapeutic cell banks. In addition, these cells could
be engineered by genetic manipulation to produce
proteins of therapeutic or morphogenic importance.
In allogenic transplantation immunomodulation will
be necessary, and this may well be possible through
gene manipulation. A donor cell’s age has implica-
tions upon its ability to divide. Telomeres cap
chromosomes and are lost when cells divide, this
process being strongly implicated in cellular senes-
cence. An approach to overcome this problem is the
introduction of telomerase by gene transfection into
cells. This enzyme maintains the telomeres and thus
would allow cells to continue dividing.18
Fig. 1
Scanning electron micrographs of chondrocytes attached to a
polymer scaffold (1 centimetre = 20 micrometres).
Fig. 2
Diagram illustrating the process of tissue engineering a
construct.
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The benet of pluripotent stem cells is that they
may be directed into different cell types as required.
This offers an enormous variety of applications.
Human embryonic stem cells have been isolated
from human embryonic blastocysts.19 These stem
cells were proliferated in an undifferentiated state
and then directed into cell types representing three
embryonic germ layers. Controversy exists regarding
the ethical implications of such work, which is
currently carried out under the strictest guidelines
and controls.
The scaffold of the tissue engineered construct
The matrix component of a ‘construct’ may be
synthetic or natural, biodegradable or non-biode-
gradable. They may be described as being closed or
open cell delivery systems and, as such, exist in
brous, hydrogel, foam, or capsular forms.
Synthetic matrices can be broadly divided into
polymeric compounds (for example; polylactic acid,
polyglycolic acid, co-polymers of polyglycolic and
polylactic acid, polyethylene oxide) and bioactive
glasses (for example, Bioglass 45S5™ , US Biomater-
ials Corp, USA). The synthetic polymers can be
shaped and moulded relatively easily and have
physicochemical characteristics that may be manipu-
lated,20 but they do not themselves contribute
greatly to cell growth and differentiation or synthesis
of extracellular matrix. Investigation into bioactive
materials promises the development of resorbable
scaffolds that enhance growth of engineered tissue.21
There is also exploration into the impregnation of
scaffolds with growth factors that would be released
in a controlled way to modulate growth and
differentiation including angiogenesis within the
implant.22
Natural scaffolds include alginates,8 autologous
brin polymers23 and collagen. The naturally occur-
ring scaffold materials that are common to the matrix
of the actual tissue being replaced have the
advantage of being inherently interactive with the
implant cells.
In closed cell delivery systems the cells are
separated by semipermeable membranes from the
recipient tissue through which the cells cannot pass.
These systems have limited applications except in
the case of microcapsules made of hydrogels such as
alginate. Minimally invasive technologies can exploit
the ability of hydrogels to readily change from liquid
to gel in the development of injectable systems.
Open cell implant systems such as porous three
dimensional synthetic polymer scaffolds offer large
surface areas for diffusion, cell-cell and cell-matrix
interactions and even the ingress of new vasculature.
Bioreactors
The tissue creation process is usually carried out in a
bioreactor, which is an in vitro culture system
designed specically to develop tissue-engineered
constructs. These systems specically aim to (1)
establish spacially uniform cell distributions on three
dimensional scaffolds, (2) maintain desired concen-
trations of gases and nutrients in culture medium, (3)
provide efcient mass transfer to growing tissue and
(4) expose developing tissue to appropriate physical
stimuli (for example, pulsatile ow to engineer
vessels).24,25
Applications in otorhinolaryngology–head and neck
surgery
Reconstruction of the soft tissues and skeletal
elements of the face offer particular functional and
aesthetic challenges to the surgeon. Good results
may be obtained with modern techniques of plastic
and reconstructive surgery including local ap
reconstruction, implantation of synthetic materials,
tissue expansion and even free tissue transfer.
However, such techniques often demand specialist
skills, risk implant extrusion, cause donor site
morbidity and may require multiple operative
procedures.
Tissue engineered allograft skin is commercially
available but currently most products act only as
biological dressings. Autologous cells are cultured
and used as skin substitutes, but unfortunately this
technique is awed by the time taken for the cells to
grow. Although no commercially available skin
substitute currently has the ideal properties of a
conventional autograft, this is a realistic expectation
for the near future.26
Human nasal septal cartilage27 and a variety of
chondrocytes from other human and animal sites15,28
have been used as donor sites for the production of
three-dimensional cartilage reconstructions. None
have so far been used in the head and neck in
clinical trials. However, well publicized in vivo
animal studies show great promise.23 The potential
for reconstruction of the damaged nose including
augmentation rhinoplasty, reconstructive rhinoplasty
after rhinectomy and repair of nasal septal perfora-
tions exist. Reconstruction of the auricle for microtia
is another attractive potential application.
Laryngotracheal reconstruction techniques in the
adult and child currently include; resection and end
to end anastomoses, muscular augmentation aps,
stenting, rib cartilage grafts and tracheal allograft or
xenograft transplantation. Vacanti and Vacanti
report tracheal reconstruction in rats using poly-
glycolic acid/chondrocyte engineered constructs.20
The constructs remained patent for a number of
weeks. Work by the same group continues using co-
culture techniques to develop organs with cartilage
and luminal mucosal lining to ensure long-term
stability and patency.
Much has been written about reconstruction of the
mandible following resection for oral cavity malig-
nancy. The currently favoured technique is
vascularized free tissue transfer using composite-
grafts centred around the radius, bula or iliac crest.
There have been successful implants of Bioglass™ in
humans as a matrix-only implant for small mandib-
ular defects.29,30 Current research is aimed at larger
reconstructions with viable cell-scaffold constructs.
Oncological surgery of the head and neck often
results in the resection of neck viscera. Grower
et al.31 and Vacanti et al.20 have replaced segments of
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resected oesophagus in dogs and rats respectively
with co-polymer tubes that became epithelialized
and colonized by connective tissue allowing resump-
tion of a semi-solid diet. Thus it may be feasible to
engineer pharyngo-oesophageal tissue even if only
as passive food conduits. Following glossectomy
various techniques of reconstruction are employed,
often with signicant donor site morbidity. Although
there have been no reports of tongue reconstruction
in animal or human subjects with prefabricated
implants, the basic science of myocyte growth and
replication is being unravelled, such that tissue-
engineered reconstruction of the tongue may one
day become a reality.
Endocrine tissue engineering is well advanced.
Initially focused on pancreatic islet cell replacement
for diabetic mellitus, research has now broadened to
consideration of organs such as the parathyroid
glands. Experiments are ongoing with parathyroid
cells encapsulated in selectively permeable
membranes for eventual transplantation in hypo-
parathyroid patients.32 This provides the possibility
of freedom from calcium replacement therapy.
Materials science has long been involved in
ossicular reconstruction and indeed bioactive cera-
mics are established materials for implants,33
however if seeded with osteoblasts thus subsequently
ossifying into living bony ossicles, implant survival
may be assured.
Closure of cranial vault defects has been carried
out in rats.20 In the future these methods may be
usefully employed to obliterate mastoid cavities or
defects such as those left after approaches to the
skull base.
Progress is being made in our understanding of
vestibulocochlear hair cell biology and the regenera-
tion potential of avian hair cells has been
documented.34 As the mechanisms governing this
process are unravelled and with the possibility of
exploiting embryonic stem cell technology it may
well be that organs with the differentiation commit-
ment of the cochlea are within the scope of repair or
replacement.35
By stem cell or supporting cell implantation to
initiate axonal regeneration and directed neuronal
networking, neuronal tissue engineering develop-
ments offer the prospect of repairing peripheral
nerve36 and central nervous system lesions.37
The areas where tissue engineering has entered
clinical use to date are; autologous chondrocytes for
articular cartilage repair,38 engineered skin substi-
tutes and bioactive materials for bony repair. Many
other technologies are approaching clinical trials.
Table I summarizes some of the areas in which tissue
engineering may be applied to the ENT surgery.
Conclusion
Signicant advances have been made in the basic
sciences that underpin tissue engineering. Since the
recognition of tissue engineering as a biotechnologi-
cal process in its own right, progress has been made
in drawing together much of this basic science
research. Construct implantation has been per-
formed in vivo, but largely in non-primate animals.
The obvious future stages are further in vitro studies
followed by in vivo work on primates and then
human clinical trials. Other future challenges might
include novel applications for reconstructive surgery,
the further union of genetic engineering and tissue
engineering, novel delivery approaches and devel-
oping functional complex articial organs.5
Tissue engineering is a multidisciplinary eld in
the truest sense, involving materials science, matrix
science, embryology, gene therapy, histochemistry,
cell biology, immunology, molecular biology, trans-
plant biology and clinical medicine. Although young
and largely experimental, it appears that progress in
tissue engineering has been rapid and its potential
applications vast, such that tissue engineering is sure
to change the way we practise medicine in the future.
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